Summary Abstract Lacidipine (Caldine®, Lacimen®, Lacipil®, Midotens®, Motens®) is a
once-daily, orally-administered, lipophilic dihydropyridine calcium antagonist with an …

Synopsis Lacidipine is an orally administered calcium channel blocker of the
dihydropyridine class, which shows selectivity for vascular smooth muscle over cardiac …

The clinical safety of the new dihydropyridine calcium antagonist lacidipine was assessed in
14 clinical trials, including 1,372 patients treated with lacidipine and 687 treated with an …

In a large, open, multicenter study, 2,206 outpatients with mild-to-moderate essential
hypertension were recruited by 755 cardiologists throughout France. Patients received …

Hypertension is well recognized to be an important cardiovascular risk factor and
antihypertensive therapy has been shown to decrease cardiovascular mortality and …

Objective: The aim was to review the clinical safety profile of lacidipine with the help of the
rather comprehensive datafile of the manufacturer-a novel approach which may be of some …

The clinical safety of lacidipine, a new dihydropyridine calcium antagonist, has been
assessed in a longterm, comparative study in hypertensive patients. Slowrelease (SR) …

Lacidipine is a new 1, 4-dihydropyridine (DHP) that induces a potent calcium antagonistic
activity on vascular preparations. It has a markedly slow rate of onset, but its effect is still …

Calcium channel blockers are increasingly used in the treatment of hypertension. Newer
calcium channel blockers of the dihydropyridine group have longer elimination half-lives …

The aim of this study was to compare the antihypertensive efficacy and tolerability of
lacidipine, a new dihydropyridine calcium antagonist, and slow-release nifedipine (SR) in …